Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23594368 | 0.84 | ALDH1A1 (0.34) | KDM4ETDP1ALDH1A1KMT2AMEN1 | |
| SCHEMBL24926368 | 0.82 | HRH3 (0.40) | KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL23594105 | 0.80 | CYP2D6 (0.38) | HSD11B1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL23594109 | 0.79 | ALDH1A1 (0.36) | HSD11B1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL26808452 | 0.79 | HSD11B1 (0.50) | HSD11B1KDM4ETDP1ALDH1A1GAA | |
| SCHEMBL23594628 | 0.78 | ALDH1A1 (0.37) | HSD11B1KDM4EALDH1A1RAB9A | |
| SCHEMBL23594107 | 0.78 | KDM4E (0.32) | KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL23594364 | 0.77 | KDM4E (0.34) | KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL24926121 | 0.76 | KDM4E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL23729436 | 0.74 | HSD11B1 (0.44) | HSD11B1KDM4ETDP1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | HSD11B1 3266/4885KDM4E 1022/4885TDP1 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.